18F-FDG PET/CT作为西妥昔单抗联合同步放化疗后头颈鳞癌早期疗效监测影像生物标志物的评估
本研究前瞻性纳入54例头颈癌患者,在治疗前、放化疗结束后1周及3个月三个时间点行FDG-PET/CT,评估其早期识别治疗反应及预测无进展生存(PFS)的能力。结果显示放化疗后1周的PET/CT2无预后价值,而3个月时PET/CT3的SUVmax和病灶直径是PFS的独立预测因素,影像学应答者PFS显著更长。
要点
- 放化疗结束后1周的PET/CT2不能预测PFS,也无法识别需巩固治疗的高危患者。
- 放化疗结束后3个月的PET/CT3中,SUVmax和病灶直径是PFS的独立预测因素。
- PET/CT3影像学应答者较非应答者PFS显著更长,或可作为预后生物标志物。
核心结论
- 头颈癌放化疗后1周的早期反应可通过PET/CT准确评估,但PET/CT2对PFS无预后价值。
- PET/CT3的SUVmax和病灶直径是PFS的独立预测因素,影像学应答者PFS显著更长。
研究设计与样本
- 单中心前瞻性随机研究,2012年3月至2015年4月共纳入54例头颈癌患者。
- 患者在治疗前(PET/CT1)、放化疗结束后1周(PET/CT2)和结束后3个月(PET/CT3)行FDG-PET/CT,随访至少18个月。
主要发现
- 32例(64%)持续无病,11例(22%)复发,7例(14%)持续带瘤。
- PET/CT2和PET/CT3时点应答者与非应答者间代谢参数比值无显著差异(P > .05)。
- 多因素回归显示PET/CT3时点的SUVmax和直径均为PFS的独立预测因素。
- PET/CT3影像学应答者较非应答者PFS显著更长(P < .01)。
关键数值与推荐
- PET/CT2时点应答者与非应答者PFS无统计学显著差异(P > .05)。
- PET/CT3时点影像学应答者较非应答者PFS显著更长(P < .01)。
临床怎么用
- 放化疗结束后1周行PET/CT不宜用于判断预后或筛选需巩固治疗的患者。
- 放化疗结束后3个月行PET/CT可依据SUVmax和病灶直径评估PFS风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine whether 18 F-PET/CT is able to identify treatment response as early as 1 week after the end of chemoradiotherapy, whether 18 F-PET/CT can identify prognostic markers concerning progression free survival and can identify patients who need additional consolidation therapy. METHODS: A total of 54 patients with head and neck cancer were prospectively enrolled in this single-center, randomized study from 03/2012-04/2015. Patients underwent FDG-PET/CT imaging at three predefined time points: pretreatment (PET/CT1), 1 week postprimary radiochemotherapy (PET/CT2) and 3 months postprimary radiochemotherapy (PET/CT3). Tumors were assessed quantitatively based on size and glucose uptake (SUVmax) concerning response at each time point. Response assessment was correlated with progression free survival. All patients had a minimum follow-up period of 18 months. Multivariate regression analysis was performed to find independent predictors for progression free survival (PFS). RESULTS: Thirty-two (32) patients (64%) overall remained disease free, 11 patients (22%) had recurrence and 7 patients (14%) had persistent disease. There was no significantly different metabolic parameter ratio found concerning responders and nonresponders at posttreatment (PET/CT2 and 3) time points (P > .05) during clinical follow-up. Multivariate regression analysis demonstrated both SUVmax and diameter assessed at time point PET/CT3 represent independent predictors of progression free survival (PFS). There was also no statistically significant difference in PFS between responders and nonresponders by means of PET/CT2 in both study arms (P > .05). Imaging responders at time point PET/CT3 showed a significantly longer PFS compared to nonresponders after the end of consolidation therapy (P < .01). CONCLUSIONS: Early response of head/neck cancer after radiochemotherapy can be accurately assessed with PET/CT 1 week after RCT. SUVmax and lesion diameter are independent predictors of PFS at time point PET/CT3. PET/CT2 has no prognostic value concerning PFS and cannot identify high risk patients for consolidation therapy. Imaging responders showed a significantly longer PFS compared to nonresponders and therefore PET/CT might serve as a prognostic biomarker. TRIAL REGISTRATION: Clinical Trials.gov identifier: NCT01435252.
引用
- de Galiza Barbosa F, Riesterer O, Tanadini-Lang S, et al. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma. Head Neck. 2019. PMID: 31705729. doi:10.1002/hed.25975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。